Iovance Biotherapeutics, Inc. (IOVA)
14.09
-0.05
(-0.35%)
USD |
NASDAQ |
Oct 23, 16:00
14.08
-0.01
(-0.07%)
After-Hours: 20:00
Iovance Biotherapeutics Gross Profit Margin (Quarterly) : 46.54% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 46.54% |
| March 31, 2026 | 28.55% |
| December 31, 2025 | 39.31% |
| September 30, 2025 | 29.61% |
| June 30, 2025 | -4.92% |
| March 31, 2025 | -12.32% |
| December 31, 2024 | 29.87% |
| Date | Value |
|---|---|
| September 30, 2024 | 22.41% |
| June 30, 2024 | -18.13% |
| March 31, 2024 | -1.65K% |
| December 31, 2023 | -2.82K% |
| September 30, 2023 | -2.08K% |
| June 30, 2023 | -3.24K% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| AVITA Medical, Inc. | 81.87% |
| Halozyme Therapeutics, Inc. | 77.40% |
| CareDx, Inc. | 73.37% |
| Amgen, Inc. | 72.08% |
| Xencor, Inc. | 95.24% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -40.70% |
| Return on Assets | -31.70% |
| Return on Invested Capital | -38.03% |
| Profit Margin (Quarterly) | -47.64% |
| Operating Margin (Quarterly) | -52.26% |
| Return on Net Operating Assets | -49.41% |